IPAB rejects Monsanto plant patent
15-07-2013
Image: Novartis AG
India’s Supreme Court has rejected pharmaceutical company Novartis’s application to patent an updated version of its leukaemia drug Glivec, agreeing with the Comptroller General that it lacked novelty.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
Novartis, Glivec, India, Supreme Court, patent, pharmaceuticals
